Preliminary Evaluation of an Ultrasound-Guided Robotic System for Autonomous Percutaneous Intervention
Authors:
Pratima Mohan,
Aayush Agrawal,
Niravkumar A. Patel
Abstract:
Cancer cases have been rising globally, resulting in nearly 10 million deaths in 2023. Biopsy, crucial for diagnosis, is often performed under ultrasound (US) guidance, demanding precise hand coordination and cognitive decision-making. Robot-assisted interventions have shown improved accuracy in lesion targeting by addressing challenges such as noisy 2D images and maintaining consistent probe-to-s…
▽ More
Cancer cases have been rising globally, resulting in nearly 10 million deaths in 2023. Biopsy, crucial for diagnosis, is often performed under ultrasound (US) guidance, demanding precise hand coordination and cognitive decision-making. Robot-assisted interventions have shown improved accuracy in lesion targeting by addressing challenges such as noisy 2D images and maintaining consistent probe-to-surface contact. Recent research has focused on fully autonomous robotic US systems to enable standardized diagnostic procedures and reproducible US-guided therapy. This study presents a fully autonomous system for US-guided needle placement capable of performing end-to-end clinical workflow. The system autonomously: 1) identifies the liver region on the patient's abdomen surface, 2) plans and executes the US scanning path using impedance control, 3) localizes lesions from the US images in real-time, and 4) targets the identified lesions, all without human intervention. This study evaluates both position and impedance-controlled systems. Validation on agar phantoms demonstrated a targeting error of 5.74 +- 2.70 mm, highlighting its potential for accurately targeting tumors larger than 5 mm. Achieved results show its potential for a fully autonomous system for US-guided biopsies.
△ Less
Submitted 14 October, 2024;
originally announced October 2024.
A Biologically Plausible Benchmark for Contextual Bandit Algorithms in Precision Oncology Using in vitro Data
Authors:
Niklas T. Rindtorff,
MingYu Lu,
Nisarg A. Patel,
Huahua Zheng,
Alexander D'Amour
Abstract:
Precision oncology, the genetic sequencing of tumors to identify druggable targets, has emerged as the standard of care in the treatment of many cancers. Nonetheless, due to the pace of therapy development and variability in patient information, designing effective protocols for individual treatment assignment in a sample-efficient way remains a major challenge. One promising approach to this prob…
▽ More
Precision oncology, the genetic sequencing of tumors to identify druggable targets, has emerged as the standard of care in the treatment of many cancers. Nonetheless, due to the pace of therapy development and variability in patient information, designing effective protocols for individual treatment assignment in a sample-efficient way remains a major challenge. One promising approach to this problem is to frame precision oncology treatment as a contextual bandit problem and to apply sequential decision-making algorithms designed to minimize regret in this setting. However, a clear prerequisite for considering this methodology in high-stakes clinical decisions is careful benchmarking to understand realistic costs and benefits. Here, we propose a benchmark dataset to evaluate contextual bandit algorithms based on real in vitro drug response of approximately 900 cancer cell lines. Specifically, we curated a dataset of complete treatment responses for a subset of 7 treatments from prior in vitro studies. This allows us to compute the regret of proposed decision policies using biologically plausible counterfactuals. We ran a suite of Bayesian bandit algorithms on our benchmark, and found that the methods accumulate less regret over a sequence of treatment assignment tasks than a rule-based baseline derived from current clinical practice. This effect was more pronounced when genomic information was included as context. We expect this work to be a starting point for evaluation of both the unique structural requirements and ethical implications for real-world testing of bandit based clinical decision support.
△ Less
Submitted 11 November, 2019;
originally announced November 2019.
